Literature DB >> 2859020

Comparison of the effects of recently developed alpha 2-adrenergic antagonists with yohimbine and rauwolscine on monoamine synthesis in rat brain.

D J Pettibone, A B Pfleuger, J A Totaro.   

Abstract

The effects of two recently developed alpha 2-adrenergic antagonists, RX 781094 and WY 26703, on the synthesis of norepinephrine (NE), dopamine (DA) and serotonin (5-HT) in rat brain were compared to those of yohimbine, its diastereoisomer rauwolscine, and mianserin. Intraperitoneal administration of these compounds increased cortical NE synthesis with the potency order: yohimbine, RX 781094, WY 26703 greater than rauwolscine greater than mianserin. Within a similar dose range, yohimbine, rauwolscine and WY 26703 also stimulated striatal DA synthesis and decreased hypothalamic 5-HT synthesis, while RX 781094 and mianserin were very weak or inactive. Yohimbine and the structurally-related WY 26703 were also active as DA antagonists in the gamma-butyrolactone model for DA autoreceptor function. Based on the drug-induced changes in monoamine synthesis as indication of receptor-mediated events, RX 781094 has greater selectivity as an alpha 2-antagonist than compounds structurally related to yohimbine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2859020     DOI: 10.1016/0006-2952(85)90614-8

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  11 in total

1.  Alpha 1- and alpha 2-adrenoreceptor antagonists differentially influence locomotor and stereotyped behaviour induced by d-amphetamine and apomorphine in the rat.

Authors:  S L Dickinson; B Gadie; I F Tulloch
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 2.  Brain injury: new insights into neurotransmitter and receptor mechanisms.

Authors:  H M Pappius
Journal:  Neurochem Res       Date:  1991-09       Impact factor: 3.996

3.  Neurochemical profile of EMD 45609 (carmoxirole), a dopamine DA2-receptor agonist.

Authors:  A F Haase; H E Greiner; C A Seyfried
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-06       Impact factor: 3.000

4.  Dose-response relationship for oral idazoxan effects in healthy human subjects: comparison with oral yohimbine.

Authors:  J H Krystal; C J McDougle; S W Woods; L H Price; G R Heninger; D S Charney
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

5.  Alpha 2-autoreceptor-mediated modulation of tyrosine hydroxylase activity in noradrenergic regions of the rat brain in vivo.

Authors:  F Pi; J A García-Sevilla
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-06       Impact factor: 3.000

6.  Idazoxan increases rough-and-tumble play, activity and exploration in juvenile rats.

Authors:  S M Siviy; D M Atrens; J A Menendez
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

7.  The alpha 2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats.

Authors:  Antti Haapalinna; Tiina Leino; Esa Heinonen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-18       Impact factor: 3.000

8.  The pharmacokinetic properties of yohimbine in the conscious rat.

Authors:  J W Hubbard; S L Pfister; A M Biediger; T C Herzig; T K Keeton
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-05       Impact factor: 3.000

9.  Pharmacological profile of a new potent and specific alpha 2-adrenoceptor antagonist, L-657,743.

Authors:  D J Pettibone; B V Clineschmidt; V J Lotti; J J Baldwin; J R Huff; W C Randall; J Vacca; S D Young
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-08       Impact factor: 3.000

10.  L-654,284 a new potent and selective alpha 2-adrenoceptor antagonist.

Authors:  D J Pettibone; B V Clineschmidt; V J Lotti; G E Martin; J R Huff; W C Randall; J Vacca; J J Baldwin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-06       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.